SC&H Capital Advises CAPInnoVet on its Sale to NEOGEN

SC&H Capital served as the exclusive financial advisor to CAPInnoVet, Inc. on their sale to NEOGEN Corporation (NASDAQ: NEOG).

Founded in 2014, CAPInnoVet is an Atlanta-based companion animal health products company with the mission to provide better access to high-quality and affordable pet medications to the veterinary market. The CAPInnoVet team leverages its deep understanding of the pet medication market to capitalize on industry trends and bring novel, high-value opportunities to the market.

CAPInnoVet asked SC&H Capital to find a partner that would help to accelerate the growth of their existing companion animal health products suite and further develop their innovative pipeline of new products. SC&H Capital worked with the CAPInnoVet team to identify the right partner that would not only meet these objectives but also share similar values.

Ultimately, SC&H Capital prepared the business for sale, designed a targeted process to identify potential partners that aligned both strategically and culturally, and guided the CAPInnoVet team through the diligence process to a successful close.

CAPInnoVet was acquired by NEOGEN, a publicly-traded company that develops and markets comprehensive solutions dedicated to food and animal safety. CAPInnoVet provides NEOGEN an entry point into the fast-growing $12B+ retail parasiticide market while providing a partner to CAPInnoVet that shares its vision and values.

Read the Full Press Release

Transaction Leaders

Matthew Everett

Principal

Christopher Helmrath

Managing Director

SC&H
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.